Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Internal documents from the UK's NHS suggest that funding Gilead's hep C cure Sovaldi for 20,000 patients per year would cost the government more than $1.6 billion per year, Pharmafile reports—a price that is considered "prohibitive" by senior NHS officials.
The UK's National Institute for Health and Care Excellence (NICE) gave Sovaldi a qualified "yes" back in August, recommending its funding for the treatment of at least three genotypes of HCV.
Several public health advocates criticized the NHS briefing document analysis as being short-sighted considering that Sovaldi has shown to have a nearly 90% cure rate.
http://www.biopharmadive.com/news/is-the-uks-nhs-about-to-snub-sovaldi/318418/
The UK's National Institute for Health and Care Excellence (NICE) gave Sovaldi a qualified "yes" back in August, recommending its funding for the treatment of at least three genotypes of HCV.
Several public health advocates criticized the NHS briefing document analysis as being short-sighted considering that Sovaldi has shown to have a nearly 90% cure rate.
http://www.biopharmadive.com/news/is-the-uks-nhs-about-to-snub-sovaldi/318418/